{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:07:24Z","timestamp":1786705644764,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Klebsiella pneumoniae<\/jats:italic> is an opportunistic pathogen causing nosocomial and community-acquired infections. <jats:italic>Klebsiella<\/jats:italic> has developed resistance against antimicrobials including the last resort class; carbapenem. Currently, treatment options for carbapenem-resistant-<jats:italic>Klebsiella<\/jats:italic> (CRK) are very limited. This study aims to restore carbapenem effectiveness against CRK using celastrol and thymol. Clinical <jats:italic>Klebsiella<\/jats:italic> isolates were identified using biochemical and molecular methods. Antimicrobial susceptibility was determined using disk-diffusion method. Carbapenemase-production was tested phenotypically and genotypically. Celastrol and thymol-MICs were determined and the carbapenemase-inhibitory effect of sub-MICs was investigated. Among 85 clinical <jats:italic>Klebsiella<\/jats:italic> isolates, 72 were multi-drug-resistant and 43 were meropenem-resistant. Phenotypically, 39 isolates were carbapenemase-producer. Genotypically, <jats:italic>bla<\/jats:italic><jats:sub>NDM1<\/jats:sub> was detected in 35 isolates, <jats:italic>bla<\/jats:italic><jats:sub>VIM<\/jats:sub> in 17 isolates, <jats:italic>bla<\/jats:italic><jats:sub>OXA<\/jats:sub> in 18 isolates, and <jats:italic>bla<\/jats:italic><jats:sub>KPC<\/jats:sub> was detected only in 6 isolates. Celastrol showed significant inhibitory effect against carbapenemase-hydrolytic activity. Meropenem-MIC did not decrease in presence of celastrol, only 2-fold decrease was observed with thymol, while 4\u201364 fold decrease was observed when meropenem was combined with both celastrol and thymol. Furthermore, thymol increased CRK cell wall-permeability. Molecular docking revealed that celastrol is superior to thymol for binding to KPC and VIM-carbapenemase. Our study showed that celastrol is a promising inhibitor of multiple carbapenemases. While meropenem-MIC were not affected by celastrol alone and decreased by only 2-folds with thymol, it decreased by 4\u201364 folds in presence of both celastrol and thymol. Thymol increases the permeability of CRK-envelope to celastrol. The triple combination (meropenem\/celastrol\/thymol) could be useful for developing more safe and effective analogues to restore the activity of meropenem and other \u03b2-lactams.<\/jats:p>","DOI":"10.1038\/s41429-022-00566-y","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T11:19:17Z","timestamp":1664277557000},"page":"679-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates"],"prefix":"10.1038","volume":"75","author":[{"given":"Mahmoud Saad","family":"Abdel-Halim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momen","family":"Askoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galal","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-1998","authenticated-orcid":false,"given":"Amira M.","family":"El-Ganiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"566_CR1","doi-asserted-by":"publisher","first-page":"E3574","DOI":"10.1073\/pnas.1501049112","volume":"112","author":"KE Holt","year":"2015","unstructured":"Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D. et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci U S A. 2015;112:E3574\u201381. https:\/\/doi.org\/10.1073\/pnas.1501049112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"566_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2147\/IJGM.S214305","volume":"12","author":"J Reyes","year":"2019","unstructured":"Reyes J, Aguilar AC. Carbapenem-resistant Klebsiella pneumoniae: Microbiology key points for clinical practice. Int J Gen Med. 2019;12:437\u201336.","journal-title":"Int J Gen Med"},{"key":"566_CR3","doi-asserted-by":"crossref","unstructured":"Ko WC, Paterson DL, Sagnimeni AJ, Hansen DS, Von Gottberg A, Mohapatra S, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis. 2002;8:160\u20136.","DOI":"10.3201\/eid0802.010025"},{"key":"566_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/proceedings2020066011","volume":"66","author":"C Moya","year":"2020","unstructured":"Moya C, Maicas S. Antimicrobial resistance in Klebsiella pneumoniae strains: mechanisms and outbreaks. Proceedings. 2020;66:11. https:\/\/doi.org\/10.3390\/proceedings2020066011","journal-title":"Proceedings"},{"key":"566_CR5","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1021\/jo400236f","volume":"78","author":"RJ Worthington","year":"2013","unstructured":"Worthington RJ, Melander C. Overcoming resistance to \u03b2-lactam antibiotics. J Org Chem. 2013;78:4207\u201313.","journal-title":"J Org Chem"},{"key":"566_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/IDR.S298515","volume":"14","author":"Y Han","year":"2021","unstructured":"Han Y, Huang L, Liu C, Huang X, Zheng R, Lu Y. et al. Characterization of carbapenem-resistant Klebsiella pneumoniae ST15 clone coproducing KPC-2, CTX-M-15, and SHV-28 spread in an intensive care unit of a tertiary hospital. Infect Drug Resist. 2021;14:767\u201373.","journal-title":"Infect Drug Resist"},{"key":"566_CR7","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","volume":"69","author":"P Nordmann","year":"2019","unstructured":"Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69:S521\u20138. https:\/\/doi.org\/10.1093\/cid\/ciz824","journal-title":"Clin Infect Dis"},{"key":"566_CR8","doi-asserted-by":"publisher","first-page":"9308","DOI":"10.3390\/ijms21239308","volume":"21","author":"JC V\u00e1zquez-Ucha","year":"2020","unstructured":"V\u00e1zquez-Ucha JC, Arca-Su\u00e1rez J, Bou G, Beceiro A. New carbapenemase inhibitors: clearing the way for the \u03b2-lactams. Int J Mol Sci. 2020;21:9308. https:\/\/doi.org\/10.3390\/ijms21239308","journal-title":"Int J Mol Sci"},{"key":"566_CR9","doi-asserted-by":"publisher","first-page":"69.","DOI":"10.3389\/fmed.2017.00069","volume":"4","author":"R Casc\u00e3o","year":"2017","unstructured":"Casc\u00e3o R, Fonseca JE, Moita LF. Celastrol: A spectrum of treatment opportunities in chronic diseases. Front Med. 2017;4:69. https:\/\/doi.org\/10.3389\/fmed.2017.00069","journal-title":"Front Med"},{"key":"566_CR10","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1039\/D1BM00639H","volume":"9","author":"L Guo","year":"2021","unstructured":"Guo L, Zhang Y, Al-Jamal KT. Recent progress in nanotechnology-based drug carriers for celastrol delivery. Biomater Sci. 2021;9:6355\u201380. https:\/\/doi.org\/10.1039\/D1BM00639H","journal-title":"Biomater Sci"},{"key":"566_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","volume":"161","author":"J Liu","year":"2015","unstructured":"Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell. 2015;161:999\u20131011. https:\/\/doi.org\/10.1016\/j.cell.2015.05.011","journal-title":"Cell"},{"key":"566_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/foods10030591","volume":"10","author":"N Padilla-Monta\u00f1o","year":"2021","unstructured":"Padilla-Monta\u00f1o N, de Le\u00f3n Guerra L, Moujir L. Antimicrobial activity and mode of action of celastrol, a nortriterpen quinone isolated from natural sources. Foods. 2021;10:591","journal-title":"Foods"},{"key":"566_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12223-016-0485-4","volume":"62","author":"S-G Woo","year":"2017","unstructured":"Woo S-G, Lee S-Y, Lee S-M, Lim K-H, Ha E-J, Eom Y-B. Activity of novel inhibitors of Staphylococcus aureus biofilms. Folia Microbiologica. 2017;62:157\u201367. https:\/\/doi.org\/10.1007\/s12223-016-0485-4","journal-title":"Folia Microbiologica"},{"key":"566_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-022-02515-z","volume":"22","author":"FA Yehia","year":"2022","unstructured":"Yehia FA, Yousef N, Askoura M. Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach. BMC Microbiol. 2022;22:106 https:\/\/doi.org\/10.1186\/s12866-022-02515-z","journal-title":"BMC Microbiol"},{"key":"566_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.antiviral.2017.09.010","volume":"146","author":"C-K Tseng","year":"2017","unstructured":"Tseng C-K, Hsu S-P, Lin C-K, Wu Y-H, Lee J-C, Young K-C. Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK\/Nrf2 pathway in human hepatoma cells. Antivir Res. 2017;146:191\u2013200. https:\/\/doi.org\/10.1016\/j.antiviral.2017.09.010","journal-title":"Antivir Res"},{"key":"566_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phymed.2018.09.011","volume":"50","author":"H Sharma","year":"2018","unstructured":"Sharma H, Kumar P, Deshmukh RR, Bishayee A, Kumar S. Pentacyclic triterpenes: New tools to fight metabolic syndrome. Phytomedicine. 2018;50:166\u201377. https:\/\/doi.org\/10.1016\/j.phymed.2018.09.011","journal-title":"Phytomedicine"},{"key":"566_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3389\/fphar.2020.01047","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Lv X, Chen M, Guo Y, Ding R, Liu B, et al. Characterization of corosolic acid as a KPC-2 Inhibitor that increases the susceptibility of KPC-2-positive bacteria to carbapenems. Front Pharm. 2020;11:1047. https:\/\/doi.org\/10.3389\/fphar.2020.01047","journal-title":"Front Pharm"},{"key":"566_CR18","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1128\/JCM.42.8.3665-3669.2004","volume":"42","author":"DS Hansen","year":"2004","unstructured":"Hansen DS, Aucken HM, Abiola T, Podschun R. Recommended test panel for differentiation of Klebsiella species on the basis of a trilateral interlaboratory evaluation of 18 biochemical tests. J Clin Microbiol. 2004;42:3665\u20139.","journal-title":"J Clin Microbiol"},{"key":"566_CR19","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.21746\/ijbio.2017.04.004","volume":"6","author":"O Ahmed","year":"2017","unstructured":"Ahmed O, Dablool A. Quality improvement of the DNA extracted by boiling method in Gram negative bacteria. Int J Bioassays. 2017;6:5347\u20139. https:\/\/doi.org\/10.21746\/ijbio.2017.04.004","journal-title":"Int J Bioassays"},{"key":"566_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/aem.59.3.695-700.1993","volume":"59","author":"G Muyzer","year":"1993","unstructured":"Muyzer G, de Waal EC, Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol. 1993;59:695","journal-title":"Appl Environ Microbiol"},{"key":"566_CR21","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","volume":"38","author":"K Tamura","year":"2021","unstructured":"Tamura K, Stecher G, Kumar S. MEGA11: Molecular evolutionary genetics analysis Version 11. Mol Biol Evol. 2021;38:3022\u20137. https:\/\/doi.org\/10.1093\/molbev\/msab120","journal-title":"Mol Biol Evol"},{"key":"566_CR22","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100. 2018. https:\/\/clsi.org\/media\/1930\/m100ed28_sample.pdf."},{"key":"566_CR23","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1128\/JCM.02032-15","volume":"53","author":"F Pasteran","year":"2015","unstructured":"Pasteran F, Tijet N, Melano RG, Corso A. Simplified protocol for Carba NP test for enhanced detection of carbapenemase producers directly from bacterial cultures. J Clin Microbiol. 2015;53:3908\u201311. https:\/\/doi.org\/10.1128\/JCM.02032-15","journal-title":"J Clin Microbiol"},{"key":"566_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5897\/AJMR2015.7871","volume":"10","author":"AM El-Ganiny","year":"2016","unstructured":"El-Ganiny AM, El-mahdy AM, Abd El Latif HK, Ibrahem RH, Abdelsabour HI. Phenotypic and genotypic detection of beta-lactams resistance in Klebsiella pneumonia from Egyptian hospitals revealed carbapenem resistance by OXA and NDM genes. AfrJ Microbiol Res. 2016;10:339\u201347. https:\/\/doi.org\/10.5897\/AJMR2015.7871","journal-title":"AfrJ Microbiol Res"},{"key":"566_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.micpath.2019.05.022","volume":"132","author":"HA Abbas","year":"2019","unstructured":"Abbas HA, Kadry AA, Shaker GH, Goda RM. Impact of specific inhibitors on metallo-beta-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates. Micro Pathog. 2019;132:266\u201374. https:\/\/doi.org\/10.1016\/j.micpath.2019.05.022","journal-title":"Micro Pathog"},{"key":"566_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10616-017-0139-7","volume":"70","author":"M Gargotti","year":"2018","unstructured":"Gargotti M, Lopez-Gonzalez U, Byrne HJ, Casey A. Comparative studies of cellular viability levels on 2D and 3D in vitro culture matrices. Cytotechnology. 2018;70:261\u201373. https:\/\/doi.org\/10.1007\/s10616-017-0139-7","journal-title":"Cytotechnology"},{"key":"566_CR27","doi-asserted-by":"publisher","first-page":"106211","DOI":"10.1016\/j.ijantimicag.2020.106211","volume":"56","author":"JG Routsias","year":"2020","unstructured":"Routsias JG, Tsakogiannis D, Katsiki M, Marinou D, Mavrouli M, Vrioni G, et al. Development of a new spectrophotometric assay for rapid detection and differentiation of KPC, MBL and OXA-48 carbapenemase-producing Klebsiella pneumoniae clinical isolates. Int J Antimicrob Agents. 2020;56:106211. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106211","journal-title":"Int J Antimicrob Agents"},{"key":"566_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/apm.13015","volume":"128","author":"A Pal","year":"2020","unstructured":"Pal A, Tripathi A. Quercetin inhibits carbapenemase and efflux pump activities among carbapenem-resistant Gram-negative bacteria. Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2020;128:251\u20139. https:\/\/doi.org\/10.1111\/apm.13015","journal-title":"Acta Pathologica, Microbiologica, et Immunologica Scandinavica"},{"key":"566_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12929-019-0561-6","volume":"26","author":"HA Farrag","year":"2019","unstructured":"Farrag HA, Abdallah N, Shehata MMK, Awad EM. Natural outer membrane permeabilizers boost antibiotic action against irradiated resistant bacteria. J Biomed Sci. 2019;26:69. https:\/\/doi.org\/10.1186\/s12929-019-0561-6","journal-title":"J Biomed Sci"},{"key":"566_CR30","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1099\/mic.0.26312-0","volume":"149","author":"HL Alakomi","year":"2003","unstructured":"Alakomi HL, Saarela M, Helander IM. Effect of EDTA on Salmonella enterica serovar Typhimurium involves a component not assignable to lipopolysaccharide release. Microbiology. 2003;149:2015\u201321. https:\/\/doi.org\/10.1099\/mic.0.26312-0","journal-title":"Microbiology"},{"key":"566_CR31","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1128\/aac.00163-08","volume":"52","author":"S Petrella","year":"2008","unstructured":"Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A \u03b2-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother. 2008;52:3725\u201336. https:\/\/doi.org\/10.1128\/aac.00163-08","journal-title":"Antimicrob Agents Chemother"},{"key":"566_CR32","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/pro.697","volume":"20","author":"D King","year":"2011","unstructured":"King D, Strynadka N. Crystal structure of New Delhi metallo\u2010\u03b2\u2010lactamase reveals molecular basis for antibiotic resistance. Protein Sci. 2011;20:1484\u201391. https:\/\/doi.org\/10.1002\/pro.697","journal-title":"Protein Sci"},{"key":"566_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1107\/S2053230X17013838","volume":"73","author":"BA Lund","year":"2017","unstructured":"Lund BA, Thomassen AM, Carlsen TJO, Leiros HK. Structure, activity and thermostability investigations of OXA-163, OXA-181 and OXA-245 using biochemical analysis, crystal structures and differential scanning calorimetry analysis. Acta Crystallogr F: Struct Biol Commun. 2017;73:579\u201387.","journal-title":"Acta Crystallogr F: Struct Biol Commun"},{"key":"566_CR34","doi-asserted-by":"publisher","first-page":"e56707","DOI":"10.7554\/eLife.56707","volume":"9","author":"JZ Chen","year":"2020","unstructured":"Chen JZ, Fowler DM, Tokuriki N. Comprehensive exploration of the translocation, stability and substrate recognition requirements in VIM-2 lactamase. Elife 2020;9:e56707. https:\/\/elifesciences.org\/articles\/56707","journal-title":"Elife"},{"key":"566_CR35","volume-title":"Molecular operating environment (MOE) version 2019.0102","author":"Inc CCG.","year":"2019","unstructured":"Inc CCG. Molecular operating environment (MOE) version 2019.0102. 1010 Sherbooke St. West, Suite# 910, Montreal: Chemical Computing Group Inc; 2019."},{"key":"566_CR36","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/jcc.20933","volume":"29","author":"P Labute","year":"2008","unstructured":"Labute P. The generalized Born\/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem. 2008;29:1693\u20138. https:\/\/doi.org\/10.1002\/jcc.20933","journal-title":"J Comput Chem"},{"key":"566_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13321-019-0346-7","volume":"11","author":"C Jacquemard","year":"2019","unstructured":"Jacquemard C, Drwal MN, Desaphy J, Kellenberger E. Binding mode information improves fragment docking. J Cheminform. 2019;11:24. https:\/\/doi.org\/10.1186\/s13321-019-0346-7","journal-title":"J Cheminform"},{"key":"566_CR38","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s10096-021-04177-7","volume":"40","author":"M Sherif","year":"2021","unstructured":"Sherif M, Palmieri M, Mirande C, El-Mahallawy H, Rashed HG, Abd-El-Reheem F, et al. Whole-genome sequencing of Egyptian multidrug-resistant Klebsiella pneumoniae isolates: a multi-center pilot study. Eur J Clin Microbiol Infect Dis. 2021;40:1451\u201360. https:\/\/doi.org\/10.1007\/s10096-021-04177-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"566_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/0002-9394(82)90540-2","volume":"94","author":"AJ Flach","year":"1982","unstructured":"Flach AJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol. 1982;94:420\u20132. https:\/\/doi.org\/10.1016\/0002-9394(82)90540-2","journal-title":"Am J Ophthalmol"},{"key":"566_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijantimicag.2016.04.017","volume":"48","author":"S Pournaras","year":"2016","unstructured":"Pournaras S, Koumaki V, Spanakis N, Gennimata V, Tsakris A. Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. Int J Antimicrob Agents. 2016;48:11\u201318. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.017","journal-title":"Int J Antimicrob Agents"},{"key":"566_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","volume":"48","author":"A Barbour","year":"2009","unstructured":"Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48:575\u201384. https:\/\/doi.org\/10.2165\/11317100-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"566_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13756-019-0639-7","volume":"9","author":"S Kotb","year":"2020","unstructured":"Kotb S, Lyman M, Ismail G, Abd El Fattah M, Girgis SA, Etman A, et al. Epidemiology of Carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National healthcare-associated infections surveillance data, 2011-2017. Antimicrob Resist Infect Control. 2020;9:2. https:\/\/pubmed.ncbi.nlm.nih.gov\/31911830\/","journal-title":"Antimicrob Resist Infect Control"},{"key":"566_CR43","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41564-019-0492-8","volume":"4","author":"S David","year":"2019","unstructured":"David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4:1919\u201329. https:\/\/doi.org\/10.1038\/s41564-019-0492-8","journal-title":"Nat Microbiol"},{"key":"566_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13756-021-00950-7","volume":"10","author":"W Paveenkittiporn","year":"2021","unstructured":"Paveenkittiporn W, Lyman M, Biedron C, Chea N, Bunthi C, Kolwaite A, et al. Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016-2018. Antimicrob Resist Infect Control. 2021;10:88. https:\/\/doi.org\/10.1186\/s13756-021-00950-7","journal-title":"Antimicrob Resist Infect Control"},{"key":"566_CR45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/mdr.2021.0106","volume":"28","author":"M Karlsson","year":"2022","unstructured":"Karlsson M, Lutgring JD, Ansari U, Lawsin A, Albrecht V, McAllister G, et al. Molecular characterization of carbapenem-resistant Enterobacterales collected in the United States. Micro Drug Resist. 2022;28:389\u201397. https:\/\/pubmed.ncbi.nlm.nih.gov\/35172110\/","journal-title":"Micro Drug Resist"},{"key":"566_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13756-022-01061-7","volume":"11","author":"NA Abdelaziz","year":"2022","unstructured":"Abdelaziz NA. Phenotype-genotype correlations among carbapenem-resistant Enterobacterales recovered from four Egyptian hospitals with the report of SPM carbapenemase. Antimicrob Resist Infect Control. 2022;11:13. https:\/\/doi.org\/10.1186\/s13756-022-01061-7","journal-title":"Antimicrob Resist Infect Control"},{"key":"566_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/cmr.00043-12","volume":"25","author":"L Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez L, Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012;25:661\u201381. https:\/\/doi.org\/10.1128\/cmr.00043-12","journal-title":"Clin Microbiol Rev"},{"key":"566_CR48","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/aac.01443-17","volume":"61","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e01443\u201317. https:\/\/doi.org\/10.1128\/aac.01443-17","journal-title":"Antimicrob Agents Chemother"},{"key":"566_CR49","doi-asserted-by":"publisher","first-page":"e00174","DOI":"10.1128\/aac.00174-18","volume":"62","author":"KM Papp-Wallace","year":"2018","unstructured":"Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. Relebactam is a potent inhibitor of the KPC-2 \u03b2-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62:e00174\u201318. https:\/\/doi.org\/10.1128\/aac.00174-18","journal-title":"Antimicrob Agents Chemother"},{"key":"566_CR50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acsinfecdis.5b00097","volume":"1","author":"HI Zgurskaya","year":"2015","unstructured":"Zgurskaya HI, L\u00f3pez CA, Gnanakaran S. Permeability barrier of Gram-negative cell envelopes and approaches to bypass It. ACS Infect Dis. 2015;1:512\u201322. https:\/\/doi.org\/10.1021\/acsinfecdis.5b00097","journal-title":"ACS Infect Dis"},{"key":"566_CR51","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.3390\/molecules25184125","volume":"25","author":"A Kowalczyk","year":"2020","unstructured":"Kowalczyk A, Przychodna M, Sopata S, Bodalska A, Fecka I. Thymol and Thyme essential oil new insights into selected therapeutic applications. Molecules. 2020;25:4125. https:\/\/doi.org\/10.3390\/molecules25184125","journal-title":"Molecules"},{"key":"566_CR52","doi-asserted-by":"publisher","first-page":"S2790","DOI":"10.1016\/j.arabjc.2013.10.030","volume":"10","author":"HNH Veras","year":"2017","unstructured":"Veras HNH, Rodrigues FFG, Botelho MA, Menezes IRA, Coutinho HDM, Costa JGM. Enhancement of aminoglycosides and \u03b2-lactams antibiotic activity by essential oil of Lippia sidoides Cham. and the Thymol. Arab J Chem. 2017;10:S2790\u201355. https:\/\/doi.org\/10.1016\/j.arabjc.2013.10.030","journal-title":"Arab J Chem"},{"key":"566_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/1874285801408010006","volume":"8","author":"PSX Yap","year":"2014","unstructured":"Yap PSX, Yiap BC, Ping HC, Lim SHE. Essential oils, a new horizon in combating bacterial antibiotic resistance. Open Microbiol J. 2014;8:6\u201314.","journal-title":"Open Microbiol J"},{"key":"566_CR54","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1472-765x.2008.02407.x","volume":"47","author":"J Xu","year":"2008","unstructured":"Xu J, Zhou F, Ji BP, Pei RS, Xu N. The antibacterial mechanism of carvacrol and thymol against Escherichia coli. Lett Appl Microbiol. 2008;47:174\u20139. https:\/\/doi.org\/10.1111\/j.1472-765x.2008.02407.x","journal-title":"Lett Appl Microbiol"},{"key":"566_CR55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10717544.2020.1730522","volume":"27","author":"Z Li","year":"2020","unstructured":"Li Z, Guo Z, Chu D, Feng H, Zhang J, Zhu L. Effectively suppressed angiogenesis-mediated retinoblastoma growth using celastrol nanomicelles. Drug Deliv. 2020;27:358\u201366. https:\/\/doi.org\/10.1080\/10717544.2020.1730522","journal-title":"Drug Deliv"},{"key":"566_CR56","doi-asserted-by":"publisher","first-page":"558741","DOI":"10.3389\/fphar.2020.558741","volume":"11","author":"J Shi","year":"2020","unstructured":"Shi J, Li J, Xu Z, Chen L, Luo R, Zhang C, et al. Celastrol: a review of useful strategies overcoming its limitation in anticancer application. Front Pharmacol. 2020;11:558741. https:\/\/doi.org\/10.3389\/fphar.2020.558741","journal-title":"Front Pharmacol"},{"key":"566_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00834-8","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Luo S, Du ZW, Zhou ML, Li PW, Fu Y, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangio-proliferative glomerulonephritis. Nat Commun. 2017;8:878. https:\/\/doi.org\/10.1038\/s41467-017-00834-8","journal-title":"Nat Commun"},{"key":"566_CR58","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4093\/dmj.2019.0124","volume":"44","author":"W Hu","year":"2020","unstructured":"Hu W, Wang L, Du G, Guan Q, Dong T, Song L. et al. Effects of microbiota on the treatment of obesity with the natural product Celastrol in rats. Diabetes Metab J. 2020;44:747\u201363.","journal-title":"Diabetes Metab J"},{"key":"566_CR59","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1208\/s12249-019-1350-y","volume":"20","author":"S Chhibber","year":"2019","unstructured":"Chhibber S, Gondil VS, Singla L, Kumar M, Chhibber T, Sharma G, et al. Effective topical delivery of H-AgNPs for eradication of Klebsiella pneumoniae\u2013induced burn wound infection. AAPS PharmSciTech. 2019;20:169. https:\/\/doi.org\/10.1208\/s12249-019-1350-y","journal-title":"AAPS PharmSciTech"},{"key":"566_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82009-6","volume":"11","author":"A Salari-jazi","year":"2021","unstructured":"Salari-jazi A, Mahnam K, Sadeghi P, Damavandi MS, Faghri J. Discovery of potential inhibitors against New Delhi metallo-\u03b2-lactamase-1 from natural compounds: in silico-based methods. Sci Rep. 2021;11:2390. https:\/\/doi.org\/10.1038\/s41598-021-82009-6","journal-title":"Sci Rep"},{"key":"566_CR61","first-page":"L50","volume":"6","author":"CTP Thiyagarajan","year":"2016","unstructured":"Thiyagarajan CTP. Virtual screening and molecular docking of Ndm1 inhibitor for treatment of Klebsiella pneumonia infection. Int J Life Sci Pharma Res. 2016;6:L50\u201357.","journal-title":"Int J Life Sci Pharma Res"},{"key":"566_CR62","doi-asserted-by":"publisher","first-page":"866","DOI":"10.21037\/atm-21-1854","volume":"9","author":"J Yi","year":"2021","unstructured":"Yi J, Tian M, Hu L, Kang N, Ma W, Zhi J. et al. The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification. Ann Transl Med. 2021;9:866","journal-title":"Ann Transl Med"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00566-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00566-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00566-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T04:32:06Z","timestamp":1667881926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00566-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1038\/s41429-022-00566-y","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"21 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable as the specimens are provided by the hospital clinical laboratory and there was no direct contact with patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}